![Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease | BMC Gastroenterology | Full Text Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease | BMC Gastroenterology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12876-021-01883-6/MediaObjects/12876_2021_1883_Fig1_HTML.png)
Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease | BMC Gastroenterology | Full Text
![The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial - The Lancet Gastroenterology & Hepatology The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/f2ebb762-f98f-4396-bb20-e93779b13701/gr1.gif)
The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial - The Lancet Gastroenterology & Hepatology
![Probiotic supplementation induces remission and changes in the immunoglobulins and inflammatory response in active ulcerative colitis patients: A pilot, randomized, double-blind, placebo-controlled study - Clinical Nutrition ESPEN Probiotic supplementation induces remission and changes in the immunoglobulins and inflammatory response in active ulcerative colitis patients: A pilot, randomized, double-blind, placebo-controlled study - Clinical Nutrition ESPEN](https://clinicalnutritionespen.com/cms/attachment/0b52e0d2-ebc0-428a-9058-4c42dc0faee4/ga1_lrg.jpg)
Probiotic supplementation induces remission and changes in the immunoglobulins and inflammatory response in active ulcerative colitis patients: A pilot, randomized, double-blind, placebo-controlled study - Clinical Nutrition ESPEN
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra
![JCM | Free Full-Text | An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis JCM | Free Full-Text | An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis](https://www.mdpi.com/jcm/jcm-11-02302/article_deploy/html/images/jcm-11-02302-g001.png)
JCM | Free Full-Text | An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis
![De-escalation of immunomodulator and biological therapy in inflammatory bowel disease - The Lancet Gastroenterology & Hepatology De-escalation of immunomodulator and biological therapy in inflammatory bowel disease - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/029828a6-cbc1-41dc-8c42-06611003e9b0/gr1.jpg)
De-escalation of immunomodulator and biological therapy in inflammatory bowel disease - The Lancet Gastroenterology & Hepatology
![Frontiers | Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis Frontiers | Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis](https://www.frontiersin.org/files/Articles/837294/fmed-09-837294-HTML-r2/image_m/fmed-09-837294-g001.jpg)
Frontiers | Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis
![How Do We Treat Inflammatory Bowel Diseases to Aim For Endoscopic Remission? - Clinical Gastroenterology and Hepatology How Do We Treat Inflammatory Bowel Diseases to Aim For Endoscopic Remission? - Clinical Gastroenterology and Hepatology](https://www.cghjournal.org/cms/asset/5da7788d-f6f5-4db4-8b0e-1806a0261d61/gr1.jpg)
How Do We Treat Inflammatory Bowel Diseases to Aim For Endoscopic Remission? - Clinical Gastroenterology and Hepatology
![Relevance of monitoring transmural disease activity in patients with Crohn's disease: current status and future perspectives - Rune Wilkens, Kerri L. Novak, Christian Maaser, Remo Panaccione, Torsten Kucharzik, 2021 Relevance of monitoring transmural disease activity in patients with Crohn's disease: current status and future perspectives - Rune Wilkens, Kerri L. Novak, Christian Maaser, Remo Panaccione, Torsten Kucharzik, 2021](https://journals.sagepub.com/cms/10.1177/17562848211006672/asset/images/large/10.1177_17562848211006672-fig1.jpeg)
Relevance of monitoring transmural disease activity in patients with Crohn's disease: current status and future perspectives - Rune Wilkens, Kerri L. Novak, Christian Maaser, Remo Panaccione, Torsten Kucharzik, 2021
![Duration of sustained remission after treatment by induction with exclusive enteral nutrition and azathioprine in patients with Crohn's disease | Anales de Pediatría Duration of sustained remission after treatment by induction with exclusive enteral nutrition and azathioprine in patients with Crohn's disease | Anales de Pediatría](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S2341287921000144:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w9/qVHBXBqbSQ7FNUvNof+6+l4v03CmyaR9Rm+q8TRfDERovN5wMUmDVyYvA+rI0XvKyyiCfczR/DhKMrUSEp9oboupPfncf7qrsGq0pY8P/Sl7oj6nW2xmSfqjk2PBCo90GRcUNsZzULjZ3mQqezffGQYtUJF0VbV8WPM8TLrrfE04cWHGId6mFl+6zT6DeiIrJs/pMpagmtM2t1D9iXT1fl4XAN1pqYeJNhDl0SE4CnNsVkIZoTU7ePhPoIGLksUUtHzmXtdIdi8iLyfQ07Hkg=)
Duration of sustained remission after treatment by induction with exclusive enteral nutrition and azathioprine in patients with Crohn's disease | Anales de Pediatría
![Life | Free Full-Text | Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease Life | Free Full-Text | Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease](https://www.mdpi.com/life/life-11-01375/article_deploy/html/images/life-11-01375-g001.png)